• Avalyn Pharma completed target enrollment of 375 patients in the Phase 2b MIST trial of AP01 for progressive pulmonary fibrosis.
• Results have not been presented; topline data are expected in the second half of 2027.
• The study is designed to assess whether inhaled pirfenidone can better preserve lung function versus placebo over 52 weeks.
• Management cited earlier-stage data suggesting tolerability that could support longer time on therapy, a potential differentiator in the disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalyn Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170800PRIMZONEFULLFEED9748257) on June 17, 2026, and is solely responsible for the information contained therein.